Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a One Harvard community and culture committed to improving health.
The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.
|Chan, Brian T; Pradeep, Amrose; Prasad, Lakshmi et al. (2017) Association between internalized stigma and depression among HIV-positive persons entering into care in Southern India. J Glob Health 7:020403|
|Steinhaus, Daniel A; Mostofsky, Elizabeth; Levitan, Emily B et al. (2017) Chocolate intake and incidence of heart failure: Findings from the Cohort of Swedish Men. Am Heart J 183:18-23|
|Corsello, Steven M; Bittker, Joshua A; Liu, Zihan et al. (2017) The Drug Repurposing Hub: a next-generation drug library and information resource. Nat Med 23:405-408|
|Moghari, Mehdi H; Geva, Tal; Powell, Andrew J (2017) Prospective heart tracking for whole-heart magnetic resonance angiography. Magn Reson Med 77:759-765|
|Smeijers, Loes; Mostofsky, Elizabeth; Tofler, Geoffrey H et al. (2017) Anxiety and anger immediately prior to myocardial infarction and long-term mortality: Characteristics of high-risk patients. J Psychosom Res 93:19-27|
|Braun, Laurie R; Feldpausch, Meghan N; Czerwonka, Natalia et al. (2017) Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth Horm IGF Res 37:1-6|
|Emdin, Connor A; Klarin, Derek; Natarajan, Pradeep et al. (2017) Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes 66:2310-2315|
|Muzumdar, Mandar Deepak; Chen, Pan-Yu; Dorans, Kimberly Judith et al. (2017) Survival of pancreatic cancer cells lacking KRAS function. Nat Commun 8:1090|
|Klarin, Derek; Zhu, Qiuyu Martin; Emdin, Connor A et al. (2017) Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet 49:1392-1397|
|Chan, Brian T; Pradeep, Amrose; Prasad, Lakshmi et al. (2017) Prevalence and correlates of psychosocial conditions among people living with HIV in southern India. AIDS Care 29:746-750|
Showing the most recent 10 out of 113 publications